97.2%
Risankizumabustekinumabustekinumab-naiveustekinumab-exposedCrohn’s diseaseUK licensing authoritiesCD
…127) of the cohort, of which 12% (n=92) were serious.Conclusion Risankizumab was effective in a large, real-world, medically refractory CD c…
1articles mentioning drugs
1drug mentions
1distinct drugs extracted
0%of mentions human-reviewed
Active filtersEntity: ustekinumab-naive ×
ustekinumab-naive
This drug is selected. Its supporting articles are shown below.